HilleVax, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel vaccines. Its pipeline includes Norovirus and HIL-214. The company was founded by Maurice Hilleman and Tadataka Yamada on March 25, 2020 and is headquartered in Boston, MA.
Clinical Trials
6
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Completed
4
66.7%
Recruiting
1
16.7%
Terminated
1
16.7%
No approval data available
- Cocrystal Pharma has completed dosing the last participant in a placebo-controlled Phase 1b human challenge study of CDI-988, an oral norovirus protease inhibitor, at Emory University School of Medicine. - The trial uses the well-characterized Snow Mountain Virus strain and enrolled 40 subjects in isolated units, with symptoms and viral load as clear endpoints. - CDI-988 holds FDA fast track designation for norovirus treatment and prophylaxis, with preliminary results expected in late 2026 or early 2027. - Norovirus causes an estimated 685 million illnesses and $60 billion in global costs annually, yet no specific antiviral treatment currently exists.
- Vaxart's 400-participant Sentinel cohort showed its oral COVID-19 vaccine had fewer systemic side effects than an mRNA comparator, with no vaccine-related serious adverse events over 12 months. - The company remains on track to report top-line data from the fully enrolled ~5,000-participant main cohort targeting the KP.2 variant in the first half of 2027. - BARDA released $29 million in dedicated funding for expanded exploratory analyses including mucosal immunity profiling and sub-variant genomic sequencing. - Vaxart continues disciplined pursuit of a norovirus partnership while extending its cash runway into Q2 2027 with $64 million in cash and equivalents.
- Xoma Royalty has agreed to acquire Generation Bio, a struggling gene therapy developer, for approximately $4.29 per share in its latest "zombie biotech" acquisition. - Generation Bio raised $200 million in its 2020 IPO to develop lipid nanoparticle-based gene therapy technology but faced setbacks including disappointing preclinical results and workforce reductions. - The acquisition includes contingent value rights for shareholders, potentially providing additional payments from cash holdings, lease savings, Moderna partnership milestones, and proceeds from delivery technology sales. - Generation Bio recently slashed 90% of its workforce and began strategic review after touting RNA delivery technology for T cells, fitting Xoma's pattern of acquiring distressed biotech companies.
- XOMA Royalty Corporation reported robust financial performance in Q3 2025, receiving $43.9 million in royalties and milestones from partners in the first nine months of 2025, including $14.3 million in Q3 royalties. - The company completed strategic acquisitions of Turnstone Biologics and HilleVax while announcing planned acquisitions of LAVA Therapeutics and Mural Oncology to expand its royalty portfolio. - Key pipeline developments include Zevra Therapeutics submitting a Marketing Authorization Application to the EMA for arimoclomol in Niemann-Pick Type C disease and Rezolute Bio expecting Phase 3 ersodetug trial results in December 2025. - XOMA Royalty achieved net income of $14.1 million in Q3 2025 compared to a net loss of $17.2 million in the same period of 2024, demonstrating improved operational performance.
- XOMA Royalty's subsidiary XRA 5 Corp. will acquire clinical-stage immuno-oncology company Mural Oncology for $2.035 per share base price, potentially reaching $36.2 million total value. - The acquisition represents a 13.1% premium over Mural's recent share price and a 97.6% premium over pre-strategic review value, maximizing shareholder returns. - This deal continues XOMA's aggressive 2025 acquisition strategy, following recent mergers with HilleVax and Turnstone Biologics to expand its late-stage biotech portfolio.
- Xoma Royalty Corp. agreed to acquire Mural Oncology for $2.035-2.240 per share, valuing the deal at $35.2-38.8 million depending on closing cash balance. - The acquisition follows Mural's discontinuation of lead IL-2 therapy nemvaleukin alfa after failed Artistry-6 and 7 trials, leading to 90% workforce reduction in April. - Xoma will wind down Mural's operations as part of a growing trend where investment firms acquire struggling biotechs trading below cash value for liquidation. - The deal represents Xoma's fourth oncology acquisition this year, following purchases of Turnstone Biologics, Lava Therapeutics, and HilleVax.
- Xoma Royalty Corporation announced dual acquisitions of HilleVax and Lava Therapeutics, both companies that have struggled significantly since their public debuts several years ago. - HilleVax's value plummeted after a mid-stage trial showed its norovirus vaccine was ineffective, leading to program termination and 40% staff cuts. - Lava Therapeutics, which develops gamma delta T cell engager bispecific antibodies for cancer, laid off 30% of staff following disappointing clinical results. - Both acquisitions represent examples of "biotech zombie" companies trading below their cash holdings, highlighting a growing trend of distressed biotech consolidation.
